Selective HDAC8 Inhibitors Resolving Toxicity via Local Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors are non-selective, leading to broad spectrum inhibition of HDAC isoforms and causing significant side effects due to lack of specificity, resulting in dose-limiting toxicities and reduced therapeutic efficacy.
Innovation Solution
Development of small molecule HDAC inhibitors that are selective for HDAC8, designed to inhibit specifically HDAC8 over other HDAC isoforms, utilizing compounds of formula (I) that selectively bind to the HDAC8 catalytic site, thereby reducing toxicity and improving therapeutic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective HDAC inhibitors are used, then broad spectrum inhibition of HDAC isoforms is achieved, but significant side effects and dose-limiting toxicities occur due to lack of specificity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures that target only HDAC8's unique catalytic site features. The compounds contain zinc-binding groups and hydrophobic moieties positioned to interact with HDAC8-specific residues, creating localized specificity at the enzyme-inhibitor interface while leaving other HDAC isoforms unaffected.
Solution Approach 2:
The patent employs parameter changes by modifying key structural parameters of HDAC inhibitors, specifically the zinc-binding group configuration and hydrophobic region composition. These parameter modifications enable selective binding to HDAC8's distinct catalytic pocket, achieving high specificity (over 100-fold selectivity) while maintaining potent inhibition of HDAC8 activity.
2Reliability
If pan-HDAC inhibitors are used, then accumulation of acetylated histone proteins occurs, but lack of specificity reduces therapeutic index
Solution Approach 1:
The patent applies segmentation by dividing the HDAC inhibitor family into isoform-specific agents. Instead of using a single pan-HDAC inhibitor structure, the patent segments the approach into HDAC8-selective compounds with tailored molecular architectures that fit only the HDAC8 catalytic site, eliminating off-target effects on other HDAC isoforms.
Solution Approach 2:
The patent uses the zinc ion in the HDAC8 catalytic site as an intermediary for selective binding. The inhibitors contain zinc-binding groups that coordinate with HDAC8's zinc ion, serving as a molecular intermediary that confers specificity. This zinc-mediated binding mechanism allows selective targeting of HDAC8 while sparing other zinc-dependent HDAC isoforms through additional specific interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selective HDAC8 inhibitors demonstrate enhanced specificity and reduced toxicity, offering a more effective treatment for cancer and other diseases with fewer side effects compared to pan-HDAC inhibitors, by selectively inhibiting HDAC8 activity with a higher therapeutic index.
Implementation Method 1
small molecule HDAC inhibitors that are selective for HDAC8... selectively bind to the HDAC8 catalytic site, thereby reducing toxicity
Data Source
AI summary
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that benefit from inhibition of HDAC8 activity.